Inflammatory Bowel Disease

Featured Article
According to Dermot McGovern, MD, gastroenterologists are already practicing precision medicine in caring for patients with inflammatory bowel disease. Read on for more of his presentation at the Advances in Inflammatory Bowel Diseases virtual regional meeting April 16.
PIANO is a landmark study and registry developed to follow the effects of treatment for inflammatory bowel disease among women during pregnancy and their children following birth. Principal investigator Uma Mahadevan, MD, from the University of California San Francisco, answered some questions about this important research project.
At the Advances in Inflammatory Bowel Diseases virtual regional meeting April 16, Uma Mahadevan, MD, highlighted the safety and efficacy of ustekinumab for IBD care, and noted that new interleukin inhibitors are soon to come.
Dr Melmed, from Cedars-Sinai in Los Angeles, previews the panel session on positioning therapies in IBD that he will chair at the Advances in Inflammatory Bowel Diseases 2021 regional meeting April 16.
Researchers reveal enhanced understanding of monogenic inflammatory bowel disease is essential to improved outcomes.
Jessica R. Allegretti, MD, discusses how patients with inflammatory bowel diseases are affected by COVID-19.
Best practice statements help to guide decision-making in diagnosis, surveillance, and treatment of ulcerative colitis and Crohn disease among patients aged 60 years and older.
Clearly communicating the findings of endoscopy to pathologists, colleagues, and patients requires some standardization in the preparation of endoscopic reports, David T. Rubin, MD, told the attendees of the Advances in Inflammatory Bowel Diseases 2020 virtual meeting on December 11.
Updates to the SECURE-IBD international registry indicate that thiopurines and combination therapies may place patients with inflammatory bowel disease at heightened risk of poor outcomes from COVID-19, while anti-tumor necrosis factor agents may be protective.
With many agents to choose from and even more slated for the near future, how do you choose the best therapy for your patients with inflammatory bowel disease? William Sandborn, MD, delved into the subject at the Advances in Inflammatory Bowel Diseases 2020 virtual meeting.
Aside from formal measurements of disease activity, there are still some practical approaches to assessing inflammatory bowel disease that can be helpful for clinicians, according to a presentation by Bruce Sands, MD, at the Advances in Inflammatory Bowel Disease 2020 virtual meeting.